MedTrace Logo

A Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants

NCT05827874 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-03-04

No results posted yet for this study

Summary

The purpose of this study is to assess the effect of nipocalimab treatment on the antibody (a protein made in the body to response to a foreign substance) response following tetanus, diphtheria, pertussis (Tdap) vaccination in healthy participants at Week 4.

Conditions

  • Healthy

Interventions

DRUG

Nipocalimab

Nipocalimab will be administered as an IV infusion.

BIOLOGICAL

Tdap

Tdap will be administered as an IM injection.

BIOLOGICAL

PPSV23

PPSV23 will be administered as an IM injection.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-04-12
Primary Completion
2023-10-04
Completion
2023-10-04

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05827874 on ClinicalTrials.gov